- Ryvu Therapeutics Reports 2021 Half-Year Financial Results
- Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition
- Ryvu Therapeutics to participate in upcoming global investor conferences
- FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Ryvu Therapeutics SA (RVU:WSE) closed at 58.80, -11.98% below its 52-week high of 66.80, set on Jul 14, 2021.
44.00Dec 14 202066.80Jul 14 2021
Markit short selling activity
|Market cap||1.08bn PLN|
|EPS (TTM)||-3.40 |
Data delayed at least 15 minutes, as of Sep 28 2021.